Press and Ad-hoc Releases

Medigene Announces Strategy and Corporate Update

SHOW RELEASE

Medigene presents new data on reproducible production of TCR-T cells from MDG1011 program

SHOW RELEASE

Medigene provides Q3 2022 business update

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene participates at upcoming scientific conferences

SHOW RELEASE

Medigene provides Q2 update and 6M report 2022

SHOW RELEASE

Dr. Selwyn Ho appointed new CEO of Medigene

SHOW RELEASE

Medigene provides Q1 2022 update

SHOW RELEASE

Medigene publication details augmentation of PRAME-specific TCR-4 by PD1-41BB switch receptor

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene provides results for fiscal year 2021 and outlook

SHOW RELEASE

BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer

SHOW RELEASE

Medigene reports preliminary efficacy and immune monitoring data of Phase I of Phase I/II MDG1011 trial in blood cancers

SHOW RELEASE

Medigene achieves positive preliminary results in Phase I of Phase I/II trial of TCR-T therapy MDG1011 in blood cancers

SHOW RELEASE

New safety data shows Medigene's inducible system produces correctly-paired T cell receptors only

SHOW RELEASE